Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: A randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients
- 1 March 2001
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Critical Care Medicine
- Vol. 29 (3), 503-510
- https://doi.org/10.1097/00003246-200103000-00006
Abstract
Phase III study to confirm a trend observed in a previous phase II study showing that a single dose of lenercept, human recombinant p55 tumor necrosis factor receptor-immunoglobulin G1 (TNFR55-IgG1) fusion protein, decreased mortality in patients with severe sepsis or early septic shock. Multicenter, double-blind, phase III, placebo-controlled, randomized study. A total of 108 community and university-affiliated hospitals in the United States (60), Canada (6) and Europe (42). A total of 1,342 patients were recruited who fulfilled the entry criteria within the 12-hr period preceding the study drug administration. After randomization, an intravenous dose of 0.125 mg/kg lenercept or placebo was given. The patient was monitored for up to 28 days, during which standard diagnostic, supportive, and therapeutic care was provided. The primary outcome measure was 28-day all-cause mortality. Baseline characteristics were as follows: a total of 1,342 patients were randomized; 662 received lenercept and 680 received placebo. The mean age was 60.5 yrs (range, 17–96 yrs); 39% were female; 65% had medical admissions, 8% had scheduled surgical admissions, and 27% had unscheduled surgical admissions; 73% had severe sepsis without shock, and 27% had severe sepsis with early septic shock. Lenercept and placebo groups were similar at baseline with respect to demographic characteristics, simplified acute physiology score II-predicted mortality, profiles of clinical site of infection and microbiological documentation, number of dysfunctioning organs, and interleukin-6 (IL-6) plasma concentration. Lenercept pharmacokinetics were similar in severe sepsis and early septic shock patients. Tumor necrosis factor was bound in a stable manner to lenercept as reflected by the accumulation of total serum tumor necrosis factor α concentrations. There were 369 deaths, 177 on lenercept (27% mortality) and 192 on placebo (28% mortality). A one-sided Cochran-Armitage test, stratified by geographic region and baseline, predicted 28-day all-cause mortality (simplified acute physiology score II), gave a p value of .141 (one-sided). Lenercept treatment had no effect on incidence or resolution of organ dysfunctions. There was no evidence that lenercept was detrimental in the overall population. Lenercept had no significant effect on mortality in the study population.Keywords
This publication has 10 references indexed in Scilit:
- Anti-inflammatory therapies to treat sepsis and septic shockCritical Care Medicine, 1997
- p55 Tumor Necrosis Factor Receptor Fusion Protein in the Treatment of Patients With Severe Sepsis and Septic ShockJAMA, 1997
- Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrationsCritical Care Medicine, 1997
- Treatment of Septic Shock with the Tumor Necrosis Factor Receptor:Fc Fusion ProteinNew England Journal of Medicine, 1996
- The pathogenesis of septic shockJournal of Infection, 1995
- Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor-immunoglobulin G fusion proteins in an animal model of gram-negative sepsis.The Journal of Experimental Medicine, 1994
- The Pathophysiology of Tumor Necrosis FactorsAnnual Review of Immunology, 1992
- Protection against endotoxic shock by a tumor necrosis factor receptor immunoadhesin.Proceedings of the National Academy of Sciences of the United States of America, 1991
- Recombinant soluble tumor necrosis factor receptor proteins protect mice from lipopolysaccharide‐induced lethalityEuropean Journal of Immunology, 1991